Methods: Our study at Karolinska University Hospital, Stockholm, Sweden, focused on women with and without mood disorders and their children. Information on pharmacotherapy, mental health, delivery and neonatal complications was retrospectively collected from electronic patient records. Children were tested in a blinded manner at four to five years of age with the Wechsler Preschool and Primary Scale of Intelligence, 3rd edition. Maternal health, child health and social situations were evaluated.
therapy during pregnancy have a high risk of disease recurrence (8) . Late pregnancy lithium exposure has been associated with neonatal adaptation difficulties, including hypotonia, cyanosis, hypothyroidism, neonatal diabetes insipidus, bradycardia and respiratory disorders (9, 10) . A large, population-based study from Sweden reported an increased risk of infants being small for gestational age, as well as neonatal hypoglycaemia in infants born to women with bipolar disorder, regardless of prenatal exposure to mood stabilisers (5) .
Current knowledge on the long-term outcome of prenatal lithium exposure is limited. For example, one study found that no difference in developmental outcome could be detected when 60 children prenatally exposed to lithium were compared to their unexposed siblings. However, the outcome was only assessed by parental reports (11) . A second study found no difference between 22 children exposed to lithium and an unspecified number of controls with regard to developmental milestones (12) . To our knowledge, only one systematic evaluation has been performed and this described normal development in 15 lithium-exposed children (13) . Adequate treatment of mood disorders during pregnancy is probably highly beneficial to the child as well as the mother. Untreated maternal depression and stress during pregnancy may have negative effects on child health, both neonatal and long-term outcome (14) .
The main goal of this study was to describe cognitive development in children prenatally exposed to lithium and maternal mood disorders (MMD).
METHODS

Patients
Women with mood disorders who were treated at the Affective Disorder Outpatient Clinic, Psychiatry Clinic Southwest, Stockholm, during pregnancy and who gave birth between 2006 and 2010 were identified through an internal quality register and invited to participate in the study together with their children. The patients were first approached by letter, followed by a telephone call, between 2010 and 2014, when their children were four to five years of age. Patients who were receiving inpatient psychiatric care or did not have custody of the child at the time of the study recruitment were not invited to participate. The unexposed part of the cohort, or the control group, who had not experienced mood disorders or received lithium were women who had given birth at Karolinska University Hospital Huddinge during the same year. They were identified through the Obstetrix electronic healthcare record (Siemens AG, Munich, Germany) and invited to participate. They were matched for maternal age, the child's date of birth and child's sex. The exclusion criteria were maternal psychiatric illness and, or, treatment during pregnancy. Oral and written study information was provided to all of the women before inclusion and they all provided signed, informed consent forms regarding their own participation in the study. The legal custodians of the participating children also provided informed consent for the children. Children or women with findings that needed clinical follow-up were offered referrals to appropriate facilities.
Data collection
We collected data regarding pregnancy, maternal illness and pharmacotherapy during pregnancy, including serum concentrations of lithium when applicable, from maternity healthcare records, the internal quality register at the Affective Disorder Outpatient Clinic and psychiatric healthcare records. Lithium concentrations from mothers and infants were analysed using two different methods at the Karolinska University Laboratory: the Roche AVL 9181, an ion selective electrode method, and a modular method from Roche. Maternal lithium use was defined as using lithium during any part of the pregnancy. Information on neonatal morbidity, diagnoses, laboratory measurements and interventions was collected from electronic healthcare records. Information on thyroid stimulating hormone (TSH) from the neonatal screening programme was extracted from the PKU Register at the Centre for Inherited Metabolic Diseases, Karolinska University Hospital. TSH at birth was analysed with AutoDELFIA Neonatal hTSH fluoroimmune test (PerkinElmer, Wallac Oy, Turku, Finland). The earliest screening was performed at 48 hours of age. The cut-off for re-analysis was 20 lU/mL and for full clinical work up, it was 30 lU/mL.
The children were examined during one or two research visits to the Karolinska University Hospital Huddinge. This included a standardised examination by a physician (LF), who was not blinded to the exposure group, an interview with the mother regarding the child's health and social situation and routine laboratory tests, including TSH, free thyroxine, creatinine, sodium and potassium. In addition, the children were examined by a child psychologist (GB), who was blinded to exposure to maternal illness or medication, using the Wechsler Preschool and Primary Scale of Intelligence, 3rd edition (WPPSI-III). The WPPSI-III comprises seven core subtests, which make up the full scale intelligence quotient (FSIQ). The verbal intelligence quotient (VIQ) and performance intelligence quotient (PIQ) were estimated from three subtests each, and processing speed quotient (PSQ) was calculated from one core and one supplemental subtest (15) . One child had recently been tested with WPPSI-III in a clinical setting by another psychologist and the results from that test was made available to the researchers.
The mothers completed self-evaluation questionnaires before or during the research visit, including the Patient Health Questionnaire 9, which assessed current symptoms of depression (16) , the Alcohol Use Disorders Identification Test (AUDIT) and the Drug Use Disorders Identification Test (DUDIT). We used the AUDIT-C, which consists of the first three questions of the AUDIT tool. A structured interview, developed for this study, was conducted with the mother at the research visit, including information on episodes of mood disorder since delivery, how long the episodes lasted, psychiatric inpatient care, current pharmacological treatment, the social situation around the time of delivery and the current social situation. The social situation covered six areas -occupational situation, economic situation, housing, relationships, own children's situation and contacts with authorities -and was rated in a three-step ordinal scale as no or small problems, moderate problems or severe problems, at the time around delivery and the time of the study. The results of these questions were converted into the binary variable social problems, defined as having either moderate problems with two or more areas or severe problems in one area or more at any time. The interview was performed by one of two psychiatrists (MA or ML) or a psychiatric nurse (IRE). Due to the information provided by the mother during the interview, they were not blinded to the maternal medication and psychiatric history.
Statistical methods
Data were analysed using Stata, version 13.1 (StataCorp, College Station, TX, USA). Fisher's exact test was used for dichotomous outcomes and Kruskal-Wallis or Wilcoxon rank sum test for non-normally distributed continuous variables, such as age or time in episodes. Spearman's correlation test was used to test the correlation between maternal and infant lithium concentrations.
The different WPPSI-III scales were tested using regression analyses to find any association between the independent variable MMD and the outcome. No MMD was used as the reference category, with one dummy variable used for MMD with lithium and another one for MMD without lithium. A few subjects lacked the cognitive ability to complete the FSIQ, VIQ and PSQ tests. We assumed left censoring, namely that their IQ score was, at the most, equal to the lowest possible score on each of these tests. Due to this feature, we present descriptive data on WPPSI-III using medians and interquartile ranges (Table 4) and use a Tobit regression model for FSIQ,VIQ and PSQ ( Table 5 ). The Tobit regression was developed to handle left censoring, as standard methods give inconsistent estimates (17) . PIQ was analysed using a linear regression model, as all subjects completed this test. The analyses were carried out with and without adjustment. In some analyses, we adjusted for potential confounders such as maternal education and social problems. In the other analyses, we also included potential mediators between exposure and outcome, including premature birth, whether there were mood disorder episodes during pregnancy, number of postpartum months and the number of prescribed drugs used during pregnancy, with neurotropic drugs counted individually and other drugs grouped into other medication. We chose which variables to adjust for by testing them in a separate model, one by one, against FSIQ, VIQ, PIQ and PSQ and included variables with a p value of <0.2 in any of the analyses (18) . In all the other statistical tests, a significance level of p < 0.05 was used.
Four of the children in the study were siblings, which made the data dependent. A regression model using clusterrobust standard errors was tested, but led to an unstable model in one analysis. All analyses were, therefore, performed without cluster-robust standard errors and in general, no relevant differences were found between the cluster models and the regular models.
The study was approved by the Regional Ethics Board in Stockholm (2011/96-31/2).
RESULTS
Maternal health during and after pregnancy
A total of 37 women with MMD were eligible to participate but 12 (32%) declined and one woman was not contacted because she was receiving inpatient care at the time of the study. We included 24 women with 27 pregnancies and 28 children, including one set of twins and three sibling pairs. The control group, also referred to as the no MMD group, consisted of 11 mother-child pairs where the woman had no mood disorder during pregnancy. This represented 30% of the 37 eligible women with no mood disorder who were invited to participate. Table 1 describes the three groups of participating mothers. The first group had MMD and no reported use of lithium during pregnancy, the second had MMD and lithium use during some part of the pregnancy and the third was the control group with no MMD during pregnancy. A high level of education was noted in all three groups and two-thirds (18/27) of the women with mood disorders had a postsecondary education (Table 1) .
There was a tendency towards differences in the total time of the mood disorder episodes after delivery for women with MMD without lithium therapy during pregnancy compared to those with MMD with lithium therapy, at a median of eight months versus one month, respectively (p: 0.06). The results for the depression scale Patient Health Questionnaire 9 also indicated a more favourable, but not statistically significant (p: 0.12), situation for the women who used lithium prenatally compared to the group with MMD and no lithium reported (Table 2) .
Social problems were seen in all three groups, according to the structured interview. No significant differences were seen between the MMD and lithium group versus MMD and no lithium group (p: 0.19) and the MMD and no MMD groups (p: 0.20).
None of the participants had substantial illicit drug use. One woman in the MMD group scored one point in the DUDIT questionnaire, with regard to current use, but this was not defined as risk use. Another woman scored two points but did not currently use drugs. Five women with MMD and one woman in the control group had an AUDIT-C score of at least four points, indicating risk use. However, only one scored at least six points in the full AUDIT, which was the cut-off level for risky use.
Polypharmacy was common in the women with mood disorders. In 15 of the 27 MMD pregnancies, two or more neurotropic drugs were prescribed ( Table 1 ). The use of neurotropic drugs during pregnancy was an exclusion criterion for the unexposed part of the cohort. The women did, however, use other medication. Another medication Table 1 Description of included 27 women with a mood disorder, with (n = 20) or without (n = 7) lithium during pregnancy, and women without (n = 11) a mood disorder during pregnancy
No mood disorder (n = 11) Lithium during pregnancy (n = 20)
No lithium during pregnancy (n = 7)* Occurrence of mood disorder episodes after delivery, until time of interview (four to five years after delivery), n = number of patients with mood episodes. § § Information on maternal drug therapy during pregnancy was collected from patient records. For all patients: patient records, maternity care. For patients with mood disorder: patient records from psychiatric care.
was used in 11 of the total 38 pregnancies, including antibiotics, levothyroxine, codeine, antimigraine medication, antihypertensive agents, low molecular heparin, ibuprofen, omeprazole, insulin and antiviral medication. The use of paracetamol, vitamins or iron supplements was not included in other medications.
Lithium was used during 20 pregnancies in the MMD group: in 11 cases, it was used for the entire pregnancy; in three cases, it was used during all three trimesters, but not for the entire pregnancy; in one pregnancy, its use was limited to the first trimester and in the remaining five cases, it was only used during the second and third trimesters. The number of documented lithium concentration measurements during pregnancy ranged from 1 to 17, with a mean of nine. A total of 183 measurements were performed for the 20 mothers treated with lithium, and the concentrations ranged from 0.07 to 1.3 mmol/L, mean 0.47 mmol/L, with a standard deviation (SD) of 0.20.
Neonatal health
Information on neonatal health was available for 38 of 39 children in the study. Exposure to lithium in close proximity to the delivery was documented in 16 infants: in seven of these cases, the lithium serum concentrations were analysed in umbilical cord blood and in two cases, the measurements were repeated during the neonatal period. Cord blood lithium concentrations ranged between 0.28 and 1.57 mmol/L (mean 0.68 mmol/L, SD 0.46). No cord blood was sampled in one child exposed to lithium, but the lithium serum concentration was 0.6 mmol/L two hours after birth. The correlation between the last maternal sample (range 0.26-0.8 mmol/L) and first infant serum lithium level was low, at R 0.25 (p: 0.58).
None of the children had abnormal TSH values in the neonatal screening. The TSH level from the neonatal screening was missing for one child. That child had a normal TSH of 3.8 lU/mL when it was analysed with standard methods during the neonatal period. A TSH analysis was performed in another seven cases, due to maternal lithium treatment, and this showed that one child had a TSH of 37 lU/mL at two hours of age, but a normal result 48 hours later. All the other values were within normal range.
Hypoglycaemia, defined as a blood glucose below 2.6 mmol/L, was recorded in 13% of all the participating infants (Table 3) , and the lowest recorded plasma glucose was 0.9 mmol/L.
One malformation was reported in the study population, a case of hypospadia in one of the children not exposed to MMD.
General health and social situation of the children at age four to five years During the parental interview, 15 of 39 children were reported to have a physical or developmental disorder. There were five cases of asthma, all with intermittent treatment, four born to mothers with MMD (n = 28) and one in the control group (n = 11). Two children, one in each exposure group, had allergies. Three children in the MMD group had dermatological conditions. Two children, one in each exposure group, had ear problems. Three children, all in the MMD group, had speech or language difficulties and were seen by a speech therapist. One of these children had a low result, and one had no result on the VIQ scale. None of these two had Swedish as their first language. The third child had seen the speech therapist due to pronunciation difficulties and had a very high VIQ. One child exposed to MMD had been diagnosed with attention deficit hyperactivity disorder, and one child in the control group had an undefined neurological condition with gross and fine motor difficulties. The study was not confined to children with Swedish as their primary language.
Blood samples were drawn from 35 of 39 children during the research visit. None of them had pathological results with regard to thyroid hormones. Creatinine was elevated in six children during the first examination. The test was then repeated, and the glomerular filtration rate, as defined by the Cystatin C test, was also measured when necessary. None of the results remained abnormal.
Psychological testing at four to five years
Results from the WPPSI-III were available for all 39 children (Tables 4 and 5 ). Table 4 displays the median, 25th and 75th percentiles for each exposure group and only includes patients where the IQ results could be calculated within each test. In contrast, Table 5 presents estimated mean and 95% confidence intervals (CI) and also includes estimated values, according to the Tobit model, to account for the children with missing values for FSIQ (n = 3), VIQ (n = 2) and PSQ (n = 7). All children with missing values were in the MMD groups and these were because the child was not able to complete the tasks within the subtest. There were no statistically significant differences between the children exposed to MMD, with or without lithium, and the control group when FSIQ, VIQ and PIQ were compared. PSQ results were significantly lower for children exposed to MMD, with and without lithium, than children not exposed to MMD. Two different multivariate analyses were performed: one model adjusted for just prematurity, as this is a potential mediator rather than a confounder, and the other model adjusted for maternal level of education and social problems. The difference in PSQ remained statistically significant in the group with MMD and no lithium, compared to those without MMD in the first model (p: 0.05), and in the group with exposure to MMD and lithium compared to those without MMD in the second model (p: 0.05) ( Table 5 ). Age at testing differed significantly between the three groups (p: 0.02), but was not significantly associated to any of the outcome variables (p > 0.2) in all of the analyses and was not, therefore, included in any of the multivariate models.
The Tobit multivariate analyses that adjusted the data for maternal mood episodes during and after pregnancy, and for other prescribed drugs during pregnancy, only compared the children of mothers with mood disorders. With regard to FSIQ, the children not exposed to lithium had scores that were 6.3 IQ points lower than the offspring of mothers with MMD and lithium exposure, adjusted for maternal mood episodes during and after pregnancy. Table 3 Neonatal characteristics of study children, divided into groups by maternal mood disorder with (n = 20) and without (n = 8) lithium exposure during pregnancy and no maternal mood disorder during pregnancy (n = 11) However, this difference was not statistically significant (95% CI: À15.1 to +2.5 points, p: 0.15) ( Table 5) .
DISCUSSION
Few studies have provided detailed descriptions of the neonatal outcomes of children born to mothers with bipolar disorder or other severe mood disorders and exposure to mood stabilising drugs during pregnancy, and even fewer have presented any follow-up data beyond infancy (5, 6, 9, (11) (12) (13) 19) . Due to the often strong indication for lithium or other mood stabilising drugs during pregnancy, there has been a great need for the long-term evaluation of prenatally exposed children. Our study found that the mothers who had been treated with lithium during pregnancy had a tendency towards spending less time with Table 4 Cognitive evaluation of study children divided into groups by maternal mood disorder-with (n = 20) and without (n = 8) lithium exposure during pregnancy and no maternal mood disorder during pregnancy (n = 11). IQR = interquartile range, 25th to 75th percentile Table 5 Cognitive evaluation of study children divided into groups by maternal mood disorder, with (n = 20) and without (n = 8) lithium exposure during pregnancy, and no maternal mood disorder during pregnancy (n = 11). depressive, hypomanic or manic episodes postpartum than mothers with mood disorder but no lithium during pregnancy. Mood episodes during pregnancy were, however, more common in the lithium-treated group, making the maternal data in this small cohort difficult to interpret. Lithium is often the first choice of mood stabilising drug for patients with bipolar disorder (20) , and discontinuing lithium during pregnancy increases the risk of a mood disorder relapse (21) .
With the exception of PSQ results, we observed high IQ scores for both the control group and the MMD-exposed children, particularly in the lithium-exposed group. This could have been due to the larger proportion of women with higher education in the cohort, and we can speculate that there was a participation bias towards women with higher intelligence and, or, a stable social environment. Several clinical psychologists suspect that the Swedish standardisation of the WPPSI-III test could lead to higher test scores in children, as it is possible that the normative does not reflect the true population mean (personal communication, E Tideman, Lund University). However, this has not been established in studies. In our study, the children prenatally exposed to MMD, with or without lithium exposure, had significantly lower results for PSQ compared to the controls in the crude Tobit model analyses (Table 5) . PSQ results are difficult to interpret in children of this age and may be influenced by factors such as pencil control or attention. One study described lower results in processing speed in children born preterm and, in the same study, low PSQ was associated with low FSIQ (22) . Processing speed is important for working memory (23), but our interpretation must be cautious at this point, because of our small sample size, missing data and young cohort. The results do, however, stress the need for further studies, preferably in a larger group of school-aged children. Children with Swedish as their second language were not excluded and, although licensed interpreters were used when needed, the results may have been affected by this, especially for verbal abilities.
Maternal mood disorder and neurotropic medication during pregnancy are often described as important risk factors for adverse events in the neonatal period (3, (24) (25) (26) (27) . This study showed a relatively low neonatal morbidity, as MMD exposure had a normal neonatal period in 20 of the 27 infants with neonatal data available. We found that three of the eight infants in the group with MMD, but not exposed to lithium, were admitted to neonatal care, all due to prematurity. In addition, one pair of twins, which is a major risk factor for prematurity, was included in this group. It is worth noting that previous studies have associated prematurity and maternal bipolar disorder (5, 6) .
None of the patients exposed to lithium showed signs of neonatal hypothyroidism in the neonatal screening, defined as TSH levels above 20 lU/mL. There have been case reports of neonatal hypothyroidism in infants prenatally exposed to lithium (28) and, due to our small sample size with only 20 infants exposed to lithium, we still advise cautious observation and preferably repeated measurements of TSH and thyroxine along with measurements of lithium concentration in the exposed infant. Furthermore, patients on lithium treatment have an increased risk of hypothyroidism (9, 29) . Increased or decreased free thyroxine during pregnancy has been associated to negative outcomes on child IQ (30), and we recommend careful surveillance of thyroid function, including free thyroxine, in pregnant women receiving lithium treatment.
One limitation of this study was the sample size as a larger study may have detected clinically important differences between the groups with regard to the WPPSI-III results. Data from the pregnancies and the time periods prior to the research visit were retrospectively collected, which poses some risk of faulty data. There were missing data on pregnancy and the neonatal period in one motherchild pair. The controls were recruited from the same hospital as the exposed children, but from a different source. Children who did not perform well enough on the different subscales of the WPPSI-III did not receive an IQ result for these subscales. These missing data had to be accounted for in the statistical analysis, otherwise, there would have been a risk of overestimation of the mean scores. We used the Tobit regression model and assumed that the missing scores were, at most, equal to the lowest observed score, thereby reducing the risk of overestimation. There may also have been a risk of a type I error due to the number of statistical tests. As IQ results on different subtests are linked to each other, a Bonferroni correction would have introduced further problems and was not used. There was one set of twins and three sibling pairs in the study. This makes the data to some extent dependent and a statistical model that fitted dependent data would have been preferred. We tried to account for this statistically, but the model proved to be too unstable and was not used. Several of the women in the study had a large number of other neurotropic medications during pregnancy, making the understanding of the results more difficult. No subgroup analysis of the different drug exposures could be carried out due to the limited sample sizes, but in a larger cohort, this would have been adequate. A multitude of other factors, such as psychosocial, genetic and environmental influences, may affect cognitive development, and observational studies are always challenged by these factors. Participation bias may have been introduced in both the exposed and the unexposed part of the cohort due to a fairly low rate of inclusion, 64% and 30%, respectively. The interpretation of the results must remain cautious.
Despite above-mentioned limitations, this study adds important knowledge to this complex research field. The strengths of the study are that all but one of the children, who were aged four to five years at the time of the research visit, had been prospectively evaluated by the same child psychologist, blinded to the exposure history of the child, and that the women's health data were collected in a standardised manner. We also had information on a number of important potential confounders, such as the mother's education, social situation and alcohol use and drug abuse. But most importantly, the knowledge on how prenatal exposure to lithium may influence the children's neurodevelopment was sparse before this study, despite the fact that lithium has been used during pregnancy for decades and is highly effective at preventing relapses into potentially very serious psychiatric conditions. Despite its limited sample size, we believe that this study was the largest clinical, systematic evaluation of outcome beyond the neonatal age to date. Together with previously published research in this field, it enables cautious optimism about the relative safety of prenatal exposure to lithium, both with regard to neonatal complications and cognitive development.
